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Introduction 
Approximately 75% of breast cancers are positive for either or both the estrogen receptor 
(ER) or progesterone receptor (PgR), and estrogens are strongly implicated in initiation and 
promotion of estrogen receptor-positive breast cancer [1, 2]. Blockade of ER by antiestrogen 
(e.g. tamoxifen) or depletion of estrogens by inhibition of estrogen synthesis has therefore been 
embraced as an effective strategy in prevention and treatment of breast cancer [3-6]. 
Cytochrome P450 (CYP) isoform 19, commonly known as aromatase, is a rate-limiting enzyme 
in estrogen biosynthesis which converts androgens (such as testosterone and androstenedione) 
to estrogens (such as estradiol and estrone) [7]. Letrozole is an orally active non-steroidal 
aromatase inhibitor which has been widely used in the treatment of estrogen-dependent breast 
cancer in postmenopausal women [8, 9]. Letrozole inhibits aromatase in a competitive manner 
and the inhibitory constant (Ki) of letrozole for aromatase in human placenta microsomes is 2.1 
nM [10]. The clinical recommended dose of letrozole for treating breast cancer is 2.5 mg [8]. 
Given that orally administered letrozole is almost completely absorbed in the gastrointestinal 
tract without significant first pass elimination, the compound’s oral bioavailability is 
approximately 100% [11]. When 14C-letrozole was administered to healthy postmenopausal 
women, 90% of the radioactivity was excreted into urine, mainly as the O-glucuronide of 
carbinol-metabolite, CGP44645, indicating that the major elimination pathway of letrozole is 
hepatic oxidative metabolism followed by glucuronidation of CGP44645 and subsequent renal 
excretion [12]. Although the pharmacokinetic (PK) profile of letrozole has been extensively 
examined in clinical studies, almost all of these trials were conducted in Western populations 
[11-15]. Also, clinical evidences which prove efficacy and safety of letrozole had been mainly 
established in Western populations [8, 16-19]. Therefore, elucidation of PK profile in Japanese 
population as well as assessment of sensitivity of PK to ethnicity is indispensable in 
extrapolating the clinical data obtained in Westerners to Japanese. For compounds metabolized 
by enzymes known to have ethnic differences in activity, measuring the influence of enzyme 
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activity variance on the substrate’s PK profile is extremely important to predict the individual 
PK profile and avoid the insufficient efficacy or the unexpected safety concerns. In vitro studies 
have shown that CYP2A6 and CYP3A4 are enzymes which metabolize letrozole to CGP44645 
[20, 21]. Considerable information of human liver CYP about various substrates, inhibitors and 
inducers is available now and knowledge of the genetic polymorphism is accumulating [22]. 
Mutations in many CYP genes cause inborn errors of metabolism [23] and frequencies of the 
poor metabolizer phenotypes associated with defective CYP genes are reported to be different 
among several ethnic groups [24]. This genetic polymorphism can explain, in part, inter-
individual and ethnic difference of pharmacokinetic profile of some drugs [25-28]. Protein 
expression level of CYP3A4, one of the metabolic enzymes of letrozole, is largely induced by 
various types of substances including medicines, foods and endogenous compounds [29, 30]. 
Also, genetic polymorphism of CYP3A4 is reported in the exons, in the adjacent intronic and 5 
regulatory sequences [31]. However, no ethnic difference of genetic polymorphism relating to 
enzyme activity of CYP3A4 is reported [32]. In contrast, CYP2A6, another metabolic enzyme 
of letrozole, is known to have genetic polymorphisms and ethnic differences in the genetic 
variance have been documented [33-36]. Allele frequency of CYP2A6*1B, a 3’-untranslated 
region gene conversion product from CYP2A7 which expresses normal protein for the wild type 
gene (CYP2A6*1A), is comparable between Japanese, Korean, Chinese and Caucasian. In 
contrast, CYP2A6*4, which is a whole gene deletion and expresses no protein, is relatively 
frequently observed (10 to 20%) among Asian populations but rarely among Caucasians (1.2%). 
Allele frequencies of other genotypes which result in low enzyme activity or decreased protein 
expression (e.g. CYP2A6*7, CYP2A6*9, CYP2A6*10 and CYP2A6*11) are also higher among 
Asian than Caucasians. Plasma concentrations of letrozole are therefore suspected to potentially 
be higher among Asians than Caucasians. 
Purposes of this study are to examine pharmacokinetic profile of letrozole in Japanese 
subjects and identify factors which influence inter-individual variability and ethnic difference 
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between Japanese and Westerner in pharmacokinetic profile of letrozole using population 
pharmacokinetic (PPK) analysis, and to explore relationship between exposure of letrozole and 
its efficacy/safety to understand clinical implication of the inter-individual variability in PK 
profile of letrozole and assess necessity of dose adjustment due to the variability. During the 
study, bilirubin was found to be a significant determinant of the apparent systemic clearance 
(CL/F) of letrozole. In order to elucidate the mechanism of the effect, influence of bilirubin on 
mRNA of CYP including CYP2A6 and CYP3A4 which are metabolic enzymes of letrozole 
[21], uridine diphosphate glucuronosyltransferase (UGT) and nuclear receptors (NR) which 
relate to induction of the enzymes were examined in human hepatocytes. 
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Section 1: Pharmacokinetic profile of letrozole in Japanese 
postmenopausal women 
 
1. Prolusion 
Letrozole (Fig. 1-1) is an orally active aromatase inhibitor for treatment of breast cancer. 
Letrozole inhibits aromatase competitively with Ki value of 2.1 nM [10]. In humans, oral 
bioavailability of letrozole is approximately 100% [11]. Main elimination pathway of the 
compound is hepatic oxidative metabolism to CGP44645 (carbinol metabolite) followed by 
glucuronidation and subsequent renal excretion [12]. In vitro studies have shown that CYP2A6 
and CYP3A4 are enzymes which metabolize letrozole to CGP44645 [20, 21]. 
In order to elucidate PK profile of letrozole as well as efficacy and safety profiles in Japanese 
after once daily oral dose of letrozole at 2.5 mg, which is a targeted clinical dosage for the 
treatment of breast cancer, 2 phase I studies and 2 phase II studies were conducted in Japanese 
healthy postmenopausal women and breast cancer patients, respectively (Table 1-1). 
 
Fig. 1-1: Chemical structures of letrozole ant its carbinol metabolite CGP44645 
CYP2A6 
CYP3A4Letrozole
CGP44645 (Carbinol metabolite)OH
CN
CN
N
N
N
CN
CN
 
- 7 - 
Table 1-1: Outline of clinical studies in Japanese postmenopausal women 
Study CFEM345F1101 CFEM345F1102 CFEM345F1201 CFEM345F1203 
Phase Phase I Phase I Phase II Phase II 
Population Healthy Japanese 
postmenopausal 
women 
Healthy Japanese 
postmenopausal 
women 
Japanese 
postmenopausal 
breast cancer 
patients 
Japanese 
postmenopausal 
breast cancer 
patients 
Number 
of subjects 
12 20 31 57 
Dosage Part 1: 2.5 mg 
single dose 
Part 2: 2.5 mg 
once daily for 14 
days 
2.5 mg once daily 
for 28 days 
2.5 mg once daily 
until disease 
progression or 
any other event 
requiring 
discontinuation 
2.5 mg once daily 
until disease 
progression or 
any other event 
requiring 
discontinuation 
PK 
sampling 
Part 1: serial 
sampling a) 
Part 2: pre-dose 
on every day and 
serial sampling on 
day 14 b) 
Pre-dose on days 
1, 7, 14, 21, 27 
and 28, and serial 
sampling on days 
1 c) and 28 d) 
Pre-dose on week 
0, 4, 8, 12, 16, 20, 
24 and 28 
Pre-dose on week 
0, 4, 8, 12, 16, 20, 
24, 28, 40 and 52 
a) Pre-dose and 0.5, 1, 2 4, 6, 8, 10, 24, 48, 72, 120, 168, 240 and 336 hours post-dose 
b) Pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 240, 336, 504 and 672 hours post-
dose 
c) Pre-dose and 1, 2, 4, 6, 8 and 24 hours post dose 
d) Pre-dose and 1, 2, 4, 6, 8, 24, 48, 72 and 168 hours post-dose 
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2. Results 
1) PK profile of letrozole in healthy Japanese postmenopausal women 
Demography of subjects: The first phase I study (CFEM345F1101) consisted of 2 parts. The 
first part was single dose study at a dose of 2.5 mg. The second part was a multiple dose study 
of 2.5 mg once daily for 14 days. Twelve subjects were enrolled and completed the study. Age 
and body weight of the subjects were 60.3  5.9 years and 51.1  7.4 kg, respectively. The 
second study (CFEM345F1102) was a multiple dose study of 2.5 mg once daily for 28 days. 
Ten subjects were enrolled and completed the study. Age and body weight of the subjects were 
57.2  6.1 years and 53.6  5.3 kg, respectively. 
PK profile: After a single oral dose in part 1 of the study 1101, letrozole was rapidly absorbed, 
and maximum plasma concentration was achieved within 2 hours. After reaching peak 
concentration, plasma letrozole levels declined in a monophasic manner (Fig. 1-2). Elimination 
half-life (t1/2) varied widely among subjects, ranging from 19.3 to 149 hours (Table 1-2). Large 
inter-individual variability was also observed in the apparent systemic clearance (CL/F), which 
ranged from 0.482 to 3.26 L/hour. During the 14-day once daily administration arm, trough 
concentrations became almost constant by Day 11, and thus steady state appeared to have been 
achieved (Fig. 1-2). PK profile on Day 14 revealed that t1/2 was prolonged by repeated dosing 
(Table 1-2). Accordingly, average CL/F decreased from 1.5 to 0.74 L/hour. To confirm the 
influence of increased dosing duration on PK profile of letrozole, an additional phase I study 
(CFEM345F1102) with multiple doses for 28 days was executed. PK parameters with 28-day 
dosing were comparable to those with 14-day dosing, and no further accumulation was observed 
(Table 1-2). These results indicate that the systemic elimination of letrozole reaches saturation 
when plasma letrozole concentrations are increased by repeated dosing. 
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Fig. 1-2: Plasma concentration-time profile of letrozole after single or once daily dose 
for 14 days at 2.5 mg in healthy Japanese postmenopausal women (CFEM345F1101) 
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Individual values are shown. 
Closed and open circles show full PK profile after single dose and once daily doses for 14 days, 
respectively. Cross mark shows trough concentrations after once daily dose. 
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Table 1-2: PK parameters of letrozole in healthy Japanese postmenopausal women 
PK parameters CFEM345F1101 (N=12) CFEM345F1102 (N=10) 
Single dose Multiple dose 
[14 days] 
Single dose 
(first dose) 
Multiple dose 
[28 days] 
Tmax 
(hr) 
1.5 ± 0.6 
[0.5, 2.0] 
4.3 ± 2.3 
[1.0, 8.0] 
2.7  1.2 
[1.0, 4.0] 
5.5  6.6 
[1.0, 24.0] 
Cmax 
(ng/mL) 
43.2 ± 16.1 
[18.9, 86.4] 
186 ± 59.1 
[115, 274] 
32.4  5.45 
[25.9, 41.7] 
152  52.8 
[84.5, 235] 
t1/2 
(hr) 
68.6 ± 36.7 
[19.3, 149] 
88.9 ± 56.2 
[36.9, 227] 
NC NC 
AUC0-24hr 
(ng·hr/mL) 
559 ± 191 
[190, 891] 
3710 ± 1180 
[2180, 5700] 
465  87.9 
[358, 659] 
3300  1270 
[1700, 5470] 
AUC0-inf 
(ng·hr/mL) 
2070 ± 1150 
[767, 5185] 
NC NC NC 
CL/F 
(L/hr) 
1.50 ± 0.702 
[0.482, 3.26] 
0.741 ± 0.235 
[0.438, 1.15] 
NC 0.868  0.334 
[0.457, 1.47] 
Each value represents mean  SD [range]. 
NC: not calculated 
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2) PK profile of letrozole in Japanese postmenopausal breast cancer patients 
Demography of patients: Demography of breast cancer patients enrolled in the phase II studies 
is shown in Table 1-3. Majority of subjects were both ER and PgR positive, and received anti-
estrogen for adjuvant therapy. Demography and background characteristics were similar 
between CFEM345F1201 study and CFEM345F1203 study, and no major difference was 
observed. In order to explore relationship between PK and efficacy or safety, data from the two 
studies were pooled for the further analyses. 
PK profile: Trough concentrations of letrozole in the patients were shown in Fig. 1-3. The 
trough concentrations became almost constant 4 to 8 weeks after initiation of treatment, 
indicating achievement of steady-state. The concentration of letrozole was highly variable 
between patients, as the individual trough concentrations (average of trough concentrations in 
each patient) were in the range from 50 to 500 ng/mL. The overall mean  SD of the individual 
trough concentrations was 179  83.4 ng/mL (N=88). 
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Table 1-3: Demography and characteristics of patients 
  
CFEM345F1201
(N=31) 
CFEM345F1203 
(N=57) 
Overall 
(N=88) 
Age [year] Mean  SD 60.2  6.1 58.9  8.4 58.3  7.7 
Body weight [kg] Mean  SD 58.4  8.4 55.8  7.9 56.7  8.1 
Performance 
Status 
[n (%)] 
0 23 (74.2) 51 (89.5) 74 (84.1) 
1 8 (25.8) 6 (10.5) 14 (15.9) 
2 0 (0.0) 0 (0.0) 0 (0.0) 
Receptor status 
[n (%)] 
ER(+) and PgR(+) 13 (41.9) 34 (59.6) 47 (53.4) 
ER(+) or PgR(+) 13 (41.9) 23 (40.4) 36 (40.9) 
ER(-) and PgR(-) 0 (0.0) 0 (0.0) 0 (0.0) 
Unknown 5 (16.1) 0 (0.0) 5 (5.7) 
Prior anti-
estrogen 
[n (%)] 
None 0 (0.0) 0 (0.0) 0 (0.0) 
Adjuvant only 20 (64.5) 39 (68.4) 59 (67.0) 
Therapeutic only 5 (16.1) 11 (19.3) 16 (18.2) 
Both treatment aims 6 (19.4) 7 (12.3) 13 (14.8) 
Prior 
chemotherapy 
[n (%)] 
None 4 (12.9) 18 (31.6) 22 (25.0) 
Adjuvant only 18 (58.1) 30 (52.6) 48 (54.5) 
Therapeutic only 4 (12.9) 8 (14.0) 12 (13.6) 
Both treatment aims 5 (16.1) 1 (1.8) 6 (6.8) 
Dominant site 
[n (%)] 
Soft tissue 7 (22.6) 26 (45.6) 33 (37.5) 
Bone 12 (38.7) 8 (14.0) 20 (22.7) 
Viscera 12 (38.7) 23 (40.4) 35 (39.8) 
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Fig. 1-3: Plasma trough concentration of letrozole after once daily oral dose of letrozole 
at 2.5 mg in post-menopausal Japanese breast cancer patients 
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Individual values are shown. 
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3) Genotyping of CYP2A6 
The clinical studies showed quite substantial inter-individual variability in letrozole PK. 
Because letrozole is mainly metabolized by CYP2A6 at clinically relevant concentrations [20, 
21] and CYP2A6 is well known about genetic polymorphism [33-36], contribution of the 
genetic polymorphism to the inter-individual variability was speculated. Therefore, genotype of 
CYP2A6 was determined in subjects who participated in the clinical studies. Alleles measured 
were those with relatively high allele frequency in Japanese (Table 1-4). CYP2A6*1B expresses 
normal protein and treated as “reference allele” together with CYP2A6*1A (wild type) in the 
current analysis. CYP2A6*4 is whole gene deletion product and does not express protein at all. 
Other genotypes result in lowered enzyme activity or reduced protein expression. The CYP2A6 
genotype was determined for all subjects (N=22) who participated in the phase I studies and 59 
of 88 patients in the phase II studies (Table 1-5). Allele frequencies observed in the current 
study is comparable to the reported values in Japanese (Table 1-4). Nineteen subjects had 2 
reference alleles, while 31 possessed only 1 reference allele and 31 had no reference alleles 
(Table 1-5). One subject who grouped into the no reference allele group was genotyped as 
CYP2A6*4/*4, whole deletion of CYP2A6. 
When the subjects were stratified to 3 distinct groups based on possession of no, 1, or 2 
reference alleles (Table 1-5), plasma letrozole concentration-time profile was clearly 
distinguished by the CYP2A6 genotypes (Fig. 1-4). Subjects who possess 2 reference alleles 
showed lower letrozole concentrations while subject with no reference allele showed higher 
concentrations. 
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Table 1-4: Observed allele frequency of CYP2A6 
Allele Mutation Phenotype Allele frequency (%) 
Current study Reported frequency [36] 
Japanese Caucasian 
CYP2A6*1A Wild type Normal 17.9 16.4 58.4 
CYP2A6*1B 3’-untranslated region gene conversion with 
CYP2A7 
Normal 24.7 25.6 30.0 
CYP2A6*4 Whole deletion None 13.6 19.8 0.5 
CYP2A6*7 Point mutation in exon 9 (T1412C >> Ile471Thr) Lowered activity 17.3 12.6 0.0 
CYP2A6*8 Point mutation in exon 9 (G1454T >> Arg485Leu) Unclear 0.0 2.2 0.0 
CYP2A6*9 Point mutation in TATA box (T-48G) Lowered expression 22.8 20.7 5.2 
CYP2A6*10 Combination of CYP2A6*7 and CYP2A6*8 Lowered activity 3.7 4.3 0.0 
CYP2A6*11 Point mutation in exon 5 (T670C >> Ser224Pro) Lowered activity 0.0 0.6 No data 
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Table 1-5: Observed genotypes of CYP2A6 
Category Genotype N Genotype frequency (%) 
2 reference alleles 
(N=19) 
*1A/*1A 5 6.2 
*1A/*1B 8 9.9 
*1B/*1B 6 7.4 
1 reference allele 
(N=31) 
*1A/*4 1 1.2 
*1A/*7 5 6.2 
*1A/*9 5 6.2 
*1B/*4 5 6.2 
*1B/*7 5 6.2 
*1B/*9 9 11.1 
*1B/*10 1 1.2 
No reference allele 
(N=31) 
*4/*4 1 1.2 
*4/*7 6 7.4 
*4/*9 8 9.9 
*7/*7 4 4.9 
*7/*9 4 4.9 
*9/*9 5 6.2 
*9/*10 1 1.2 
*10/*10 2 2.5 
Total  81 100 
CYP2A6*1A and CYP2A6*1B are defined as reference allele 
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Fig. 1-4: Plasma concentration-time profile of letrozole at steady state in healthy 
Japanese postmenopausal women by CYP2A6 genotype 
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Solid line with open square represents profiles in subjects with 2 reference alleles (*1A/*1A 
[N=2], *1A/*1B [N=1], *1B/*1B [N=1]) 
Dotted line with open triangle represents profiles in subjects with 1 reference allele (*1A/*4 
[N=1], *1A/*9 [N=3], *1B/*4 [N=2], *1B/*7 [N=1], *1B/*9 [N=4]) 
Dashed line with open circle represents profiles in subjects with no reference allele (*4/*7 
[N=3], *4/*9 [N=2], *7/*9 [N=1], *9/*9 [N=1]) 
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4) PPK analyses 
It was suggested that the inter-individual variability in PK profile of letrozole observed in the 
clinical studies can be attributable to genetic polymorphism of CYP2A6. In order to identify 
factors which affect PK profile of letrozole quantitatively, data from the 4 clinical studies were 
pooled and influence of factors including CYP2A6 genotype on PK parameters of letrozole was 
investigated by means of PPK analysis using non-linear mixed model. Based on the observed 
plasma concentration-time profile, a one-compartment model with the first order elimination 
was applied in the PPK analysis. PK parameters estimated were CL/F, apparent distribution 
volume (Vd/F) and absorption rate constant (Ka). As covariates for CL/F, genotype of CYP2A6 
was evaluated based on the observation in the clinical studies. Because letrozole is mainly 
eliminated via hepatic metabolism followed by the renal excretion, laboratory test values for 
liver and kidney (AST, ALT, total bilirubin and creatinine) were also examined. Additionally, 
basic demographic data such as body weight, age and breast cancer (or healthy) were 
investigated. For Vd/F, body weight and age were investigated. Summary of covariates 
examined in the PPK analysis was shown in Table 1-6. To explore the influence of CYP2A6 
genotype on CL/F, subjects were stratified in 2 manners: (a) 2 groups based on possession of 
either at least one reference allele or no reference allele, and (b) 3 distinct groups based on 
possession of no, 1, or 2 reference alleles. The objective function values (OFV) were reduced 
from that of the basic model by 456.89 and 492.47 for groupings (a) and (b), respectively. 
Stratification to three groups decreased OFV drastically, and the difference in OFV between 
grouping (b) and that of (a) was statistically significant (OFV >3.875, corresponding to p<0.05 
by likelihood ratio test), indicating that the number of CYP2A6 reference allele strongly 
influences CL/F of letrozole. Given these results, three-way grouping (based on possession of 
no, 1, or 2 CYP2A6 reference alleles) was employed in covariate model development. 
By the first covariate screening step, body weight, age, total bilirubin, ALT, creatinine, breast 
cancer and CYP2A6 genotype were selected as potential covariates for CL/F and body weight 
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was selected for Vd/F. A full model was then developed by including all of these covariates. In 
the backward elimination from the full model, a covariate was retained in the model if 
elimination of the covariate resulted in an increase in OFV of >6.814 (corresponding to p<0.01). 
After the backward deletion step, CYP2A6 genotype (OFV: 352.93), body weight (OFV: 
26.65), total bilirubin (OFV: 7.81) and serum creatinine (OFV: 48.95) were retained as the 
covariates for CL/F and body weight (OFV: 34.78) was selected as the significant factor for 
Vd/F (Table 1-7).  The final covariate model was as follows; 
Apparent systemic clearance (L/hr): CL/F = 1.09  (PG2 × 1 + PG1 × 0.775 + PG0 × 0.412) × 
(WT/55.6)0.694 × (CRE/0.61)-0.594 × (TBIL/0.50)0.212 × 
exp(CL) 
where PG2, PG1 and PG0 are indicator functions (yes=1, no=0) for possession of 2, 1 and no 
reference alleles of CYP2A6, respectively; WT (kg), CRE (mg/dL) and TBIL (mg/dL) are body 
weight, serum creatinine and total bilirubin levels, with median values of 55.6 kg, 0.61 mg/dL 
and 0.50 mg/dL, respectively; and CL represents inter-individual random effect for CL/F, with 
a mean value of zero and variance of ωCL2. 
 
Apparent distribution volume (L): Vd/F = 99.1 × (WT/55.6)1.18 × exp(Vd) 
where Vd represents inter-individual random effect for Vd/F, with a mean value of zero and 
variance of ωVd2. 
 
Absorption rate constant (hr-1): Ka=3.92×exp(Ka) 
where Ka represents inter-individual random effect for Ka, with a mean value of zero and 
variance of ωKa2. 
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The PPK model indicates that the genotype of CYP2A6 strongly affects on CL/F of letrozole, 
CL/F of subjects who possess 1 and no reference allele will be 78% and 41% of the subjects 
who possess 2 reference alleles. The subjects with high serum creatinine will have lower CL/F 
and with high total bilirubin will have higher CL/F. The subjects with large body weight will 
have larger CL/F and larger Vd/F. 
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Table 1-6: Summary of covariates examined in the analysis 
Study CFEM345F1101 CFEM345F1102 CFEM345F1201 CFEM345F1203 Overall 
N 12 10 20 39 81 
Age (year) a) 60.3 ± 5.9 
61.5 [50.0, 68.0]
57.2 ± 6.1 
57.0 [48.0, 66.0]
60.0 ± 5.7 
59.5 [51.0, 72.0] 
59.1 ± 8.7 
57.0 [43.0, 78.0]
59.2 ± 7.3 
59 [43, 78] 
Body weight (kg) a) 51.1 ± 7.4 
51.1 [36.0, 64.4]
53.6 ± 5.3 
52.6 [47.2, 64.1]
56.8 ± 7.5 
56.0 [43.5, 70.0] 
55.9 ± 8.3 
57.1 [39.1, 83.0]
55.1 ± 7.8 
55.6 [36.0, 83.0] 
Total bilirubin (mg/dL) a) 0.59 ± 0.17 
0.50 [0.40, 0.90]
0.56 ± 0.11 
0.57 [0.36, 0.74]
0.56 ± 0.22 
0.50 [0.30, 1.40] 
0.59 ± 0.25 
0.50 [0.30, 1.50]
0.60 ± 0.20 
0.50 [0.30, 1.50] 
AST (IU/L) a) 18.3 ± 2.3 
18.5 [14.0, 22.0]
17.2 ± 3.0 
17.0 [13.0, 23.0]
25.2 ± 7.6 
23.5 [13.0, 44.0] 
26.6 ± 12.5 
22.0 [16.0, 68.0]
23.9 ± 10.2 
21.0 [13.0, 68.0] 
ALT (IU/L) a) 13.3 ± 2.6 
13.0 [10.0, 19.0]
14.1 ± 4.9 
13.5 [5.0, 22.0] 
20.6 ± 8.2 
18.0 [11.0, 43.0] 
24.0 ± 16.1 
19.0 [10.0, 71.0]
20.4 ± 12.7 
16.0 [5.0, 71.0] 
Serum creatinine (mg/dL) a) 0.81 ± 0.08 
0.80 [0.70, 0.90]
0.53 ± 0.05 
0.52 [0.46, 0.61]
0.59 ± 0.11 
0.60 [0.40, 0.80] 
0.67 ± 0.16 
0.62 [0.37, 1.40]
0.70 ± 0.20 
0.61 [0.37, 1.40] 
CYP2A6 genotype b) 
2/5/5 2/6/2 6/8/6 9/12/18 19/31/31 
a) Upper stand: Mean  SD, lower stand: median [range] 
b) Number of subjects who possess 2, 1 and no reference allele 
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Table 1-7: Estimated population pharmacokinetic parameters 
Apparent clearance 
(L/hour) 
CL/F = θCL × (PG2 × θPG2 + PG1 × θPG1 + PG0 × θPG0) 
×(WT/55.6)WT × (CRE/0.7)CRE × (TBIL/0.50)TBIL × exp(ηCL) 
Population mean 
θCL: 1.09 (0.0705) 
Covariate effect 
θPG2: Fixed to 1 
θPG1: 0.775 (0.0466) 
θPG0: 0.412 (0.0354) 
θWT: 0.694 (0.280) 
θCRE: -0.594 (0.189) 
θTBIL: 0.212 (0.171) 
Inter-subject variance 
ωCL2: 0.0903 (0.0170) 
Apparent distribution 
volume (L) 
Vd/F = θVd × (WT/51.1)WT × exp(ηVd) 
Population mean 
θVd: 99.1 (2.86) 
Covariate effect 
θWT: 1.18 (0.254) 
Inter-subject variance 
ωVd2: 0.0213 (0.00623) 
Absorption rate constant 
(hour-1) 
Ka = θKa × exp(ηKa) 
Population mean 
θKa: 3.92 (0.862) 
Inter-subject variance 
ωKa2: 1.04 (0.388) 
Letrozole concentration 
(ng/mL) 
Y = F × exp(ε) 
Residual error 
σ2: 0.0637 (0.00859) 
Each value represents estimated value (standard error of estimate). 
ω2: variance of η, σ2: variance of ε, WT: body weight [kg], CRE: serum creatinine [mg/dL], 
TBIL: total bilirubin [mg/dL] 
PG2=1 if a subject possesses 2 reference alleles, otherwise PG2=0 
PG1=1 if a subject possesses 1 reference allele, otherwise PG1=0 
PG0=1 if a subject possesses no reference allele, otherwise PG0=0 
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5) Ethnic difference of letrozole exposure between Japanese and Westerner 
In order to bridge the pivotal clinical evidence developed in Western population into 
Japanese population, comparison of PK profile between Japanese and Westerner and evaluation 
of the clinical relevance of the PK difference, if any, is necessary. 
When the trough concentration of letrozole was compared between Japanese breast cancer 
patients in the current study and Westerner in another study (ARBC3 study, Novartis internal 
data), the trough level was significantly higher in Japanese than Westerner (Fig. 1-5). Because 
the PPK analysis shows that genotype of CYP2A6 strongly effects on CL/F of letrozole, 
Japanese patients were grouped by possession of CYP2A6 reference. After grouping by CYP2A 
genotype, there was no significant difference between Westerner and Japanese with 2 reference 
alleles while there were significant differences between Westerner and Japanese with 1 or no 
reference allele. 
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Fig. 1-5: Comparison of trough letrozole concentration between Japanese and 
Westerner 
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3. Discussion 
This study was performed to assess the PK profile of letrozole in a Japanese population. 
Given that some drugs show large inter-individual variability in PK profile and can cause 
unexpected adverse events and/or insufficient efficacy [37-40], clarifying the cause of the 
variability during the early development stage is extremely important. The clinical studies in 
healthy Japanese postmenopausal women and postmenopausal breast cancer patients 
demonstrated quite substantial inter-individual variability in letrozole PK. To identify factors 
those affect disposition of letrozole, PPK analysis with non-linear mixed effects modeling was 
conducted. Covariate analysis revealed that the genotype of CYP2A6 strongly influences CL/F 
of letrozole, and the population mean of CL/F in subjects who possess only 1 reference allele 
and no reference allele were 77.5% and 41.2% of the value in the subjects who have 2 reference 
alleles, respectively. This finding indicates that the letrozole systemic clearance is largely 
attributable to metabolism by CYP2A6. In the study, there was a subject who did not express 
CYP2A6 protein, i.e., genotyped as CYP2A6*4/*4. CL/F of the subject was estimated at 0.307 
L/hr, 29% of the population mean estimate with 2 reference alleles. This result suggests that 
approximately 30% of the letrozole systemic clearance will be attributable to CYP3A4 in 
patients with 2 reference alleles, and is in good accordance with findings from an in vitro study 
that CYP2A6 is a major metabolic enzyme at a clinically relevant concentration of 0.5 µM (143 
ng/mL) and that contribution of CYP3A4 becomes more significant at higher concentrations 
[21]. 
The PPK covariate model also indicated that serum creatinine level was a significant 
covariate for letrozole clearance. When serum creatinine increased from 0.6 mg/dL to 1.2 
mg/dL, CL/F is estimated to be reduced from 1.09L/hr to 0.72 L/hr. As letrozole is mainly 
eliminated by hepatic metabolism [8, 20, 21], this correlation of CL/F with serum creatinine was 
unexpected. Activities of some metabolic enzymes have been reported to be decreased in 
patients with chronic renal failure due to inhibition of enzyme activity by uremic mediators or 
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decreased enzyme expression [41]. Reduction in letrozole clearance in subjects with decreased 
renal function may therefore be due to either or both enzyme activity inhibition or decreased 
expression of CYP2A6 or CYP3A4. Sun et al. [42] reported that change in transporter systems 
due to renal failure also contributes to change in systemic clearance of drugs exclusively 
metabolized in the liver, due to impaired liver uptake of the drugs. However, no study has 
reported any contribution of drug transporters to disposition of letrozole, and therefore 
decreased transporter activities due to renal failure will not affect letrozole clearance. 
In the current PPK model, total bilirubin was a significant covariate of the letrozole clearance 
and increase of total bilirubin from 0.5 mg/dL to 1.0 mg/dL corresponded slight increase of 
letrozole CL/F from 1.09 L/hr to 1.26 L/hr. This result was inconsistent with a clinical study in 
subjects with hepatic impairment [43]. In the hepatic impairment study, AUC in subjects with 
severe hepatic impairment of Child-Pugh grade C was approximately 2-fold of AUC in healthy 
subjects, while those in subjects with mild (Child-Pugh grade A) or moderate (Child-Pugh grade 
B) hepatic failure were unaltered. One of the potential causes of the positive correlation between 
bilirubin and CL/F of letrozole is an induction of metabolic enzymes by bilirubin. The 
elimination pathway of letrozole is metabolism to carbinol-metabolite CGP44645 by CYP2A6 
and CYP3A4, followed by glucuronidation of CGP44645 and subsequent renal excretion [12, 
21]. Currently, there is no report to show the induction of CYP2A6 or CYP3A4 by bilirubin, 
thus the influence of bilirubin on these metabolic enzymes is not known. It is reported that 
bilirubin induces UGT1A1 and UGT1A5 in rats [44]. Also, Togawa et. al. reported that 
bilirubin induces human UGT 1A1 through aryl hydrocarbon receptor dependent pathway [45]. 
It is also reported that bilirubin induces UGT1A1 by constitutive androstane receptor activation 
in human hepatocytes [46]. Although responsible enzymes for glucuronidation of CGP44645 
are not identified, induction of UGTs by bilirubin may contribute the correlation between total 
bilirubin and letrozole CL/F to some extent. However, the influence of the UGTs induction, if 
any, will be quite limited as the rate limiting step of letrozole elimination is metabolism of 
- 27 - 
letrozole to CGP44645 by CYP2A6 and CYP3A4. To clarify the mechanism of the bilirubin 
influence on CL/F of letrozole, further study is required. 
PPK model indicated that body weight was a significant covariate to CL/F and Vd/F, and 
Vd/F was almost proportional to the body weight. The estimated value of Vd/F, which can be 
assumed as an absolute distribution volume because of complete bioavailability, was 99.1L with 
body weight of 55.6 kg. It was quite large compared to blood volume [47] indicating extensive 
distribution to extra vascular peripheral tissues. 
When the trough concentration of letrozole in breast cancer patients was compared between 
Japanese and Westerner, the trough level was significantly higher in Japanese (Fig. 1-5). After 
grouping by CYP2A genotype, however, there was no significant difference between Westerner 
(78.9  37.4 ng/mL) and Japanese with 2 reference alleles (98.8  30.3 ng/mL) while there were 
significant differences between Westerner and Japanese with 1 reference allele (132  42.4 
ng/mL) or with no reference allele (243  78.2 ng/mL). Although genotyping was not performed 
in the Western patients, most of Westerner is assumed to have 2 reference alleles based on the 
literatures [33-36]. These results indicate that the observed difference between Japanese and 
Westerner will be due to genetic polymorphism of CYP2A6. The remaining difference of 
trough concentration between Westerner and Japanese with 2 reference alleles will be due to 
body weight difference (66.7  13.6 kg and 55.7  7.9 kg, respectively) as the PPK model 
shows that subjects with higher body weight will have higher CL/F and larger Vd/F. 
The PPK analysis showed that genotype of CYP2A6, body weight, serum creatinine and total 
bilirubin contribute to the inter-individual variability of letrozole PK profile. In order to validate 
the PPK model, validation with the external data set will be required. 
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4. Summary 
 There was a large inter-individual variability in PK profile of letrozole in Japanese 
postmenopausal women. 
 PPK analysis revealed that the variability is mainly attributable to genotype of CYP2A6. 
 PPK analysis also indicated that body weight, serum creatinine and total bilirubin influence 
CL/F of letrozole. 
 Difference of plasma letrozole concentration between Japanese and Westerner will be due 
to genetic polymorphism of CYP2A6. 
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Section 2: Relationship between Pharmacokinetics and clinical outcomes 
of letrozole in Japanese postmenopausal women with breast cancer 
 
1. Prolusion 
Clinical studies conducted in Japanese healthy postmenopausal women and postmenopausal 
breast cancer patients revealed that PK of letrozole is highly variable between individuals and 
the variability can mainly be attributable to genotype of CYP2A6. In case that inter-individual 
variability of a drug exposure results in the insufficient efficacy or the intolerable adverse 
events, dose-adjustment is required for proper treatment. Therefore, investigation of relationship 
between exposure and efficacy or safety is quite important for drug development. In order to 
examine the clinical relevance of the variability observed in the clinical studies of letrozole, the 
relationship between plasma letrozole concentration and its efficacy/safety was investigated by 
using the data from the phase II studies in Japanese postmenopausal women with breast cancer. 
 
2. Results 
1) Efficacy and safety results obtained in the phase II studies 
Pharmacodynamic profile (estrogen levels): Aromatase catalyzes conversion of androgens 
(testosterone and androstenedione) to estrogens (estradiol and estrone). Therefore, plasma 
estrogen levels can be surrogate markers of letrozole. In order to assess the relationship between 
plasma letrozole concentrations and estrogen levels, individual average estrogen concentrations 
after letrozole treatment were plotted against trough concentration of letrozole (Fig. 2-1). 
Estrone and estrone sulfate were completely suppressed in almost all subjects after 
administration of letrozole. The concentration of estradiol was decreased to approximately 2 
pg/mL regardless of letrozole concentration. Due to the variability of the baseline value, percent 
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of estradiol suppression from the baseline was highly variable but approximately 50% 
suppression was obtained. 
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Fig. 2-1: Relationship between plasma trough concentration of letrozole and estrogen 
level in post-menopausal Japanese breast cancer patients 
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Efficacy profile: Of the 88 breast cancer patients who participated in the clinical studies, 25 
patients achieved tumor shrinkage more than 50% from baseline by letrozole treatment (Table 
2-1). Clinical benefit rate, i.e., rate of patients who achieved CR, PR or long-NC, was 52.3%, 
indicating that letrozole can efficiently prevent tumor progression. In order to examine the 
relationship between plasma letrozole concentration and the efficacy in an exploratory manner, 
the patients were divided into 2 groups by the median value (168 ng/mL) of individual average 
plasma trough concentration of letrozole and the clinical response was compared. The response 
rate as well as the clinical benefit rate was higher in the high trough concentration group than 
the low trough concentration group. As shown in Fig. 2-2, the median value of time to 
progression (TTP) estimated by Kaplan-Meier method was also tended to be longer in the high 
trough concentration group but the difference was not statistically significant (p=0.397). 
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Table 2-1: Comparison of response rate between patients with high and low plasma 
letrozole concentration 
Efficacy criteria Overall 
(N=88) 
Grouping by letrozole concentration 
 168 ng/mL 
(N=44) 
<168 ng/mL 
(N=44) 
Clinical response 
[n, (%)] 
Complete 
response 
5 (5.7%) 2 (4.5%) 3 (6.8%) 
Partial 
response 
20 (22.7%) 12 (27.3%) 8 (18.2%) 
Long no 
change 
21 (23.9%) 11 (25.0%) 10 (22.7%) 
No change 23 (26.1%) 8 (18.2%) 15 (34.1%) 
Progressive 
disease 
17 (19.3%) 10 (22.7%) 7 (15.9%) 
Not evaluable 2 (2.3%) 1 (2.3%) 1 (2.3%) 
Response rate (%) 28.4% 31.8% 25.0% 
Clinical benefit rate (%) 52.3% 56.8% 47.7% 
Complete response: disappearance of all lesions continuing at least for 4 weeks 
Partial response: more than 50% decrease as sum of measurable lesions continuing at least for 4 
weeks 
Long no change: less than 50% decrease or less than 25% increase as sum of measurable lesion 
continuing for more than 24 weeks 
No change: less than 50% decrease or less than 25% increase as sum of measurable lesion 
continuing at least for 4 week 
Progressive disease: more than 25% increase as sum of measurable lesion. 
Response rate: (Complete response + Partial response) / total 
Clinical benefit rate: (Complete response + Partial response + Long no change) / total 
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Fig. 2-2: Comparison of TTP between patients with high and low plasma letrozole 
concentration 
Log rank test: p=0.397
 
Time to progression (TTP) was estimated by the Kaplan-Meier product limit method in each 
trough concentration group. 
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Safety profile: Fifty-eight of the 88 patients experienced drug related adverse events (AE). 
Major AEs were hot flush, increase of blood cholesterol, arthralgia and increase of liver 
enzymes (Table 2-2). Most of the AEs were grade 1 or 2 in Common Toxicity Criteria, and no 
patients required discontinuation or interruption of the letrozole treatment. These results prove 
once daily oral dose of letrozole at 2.5 mg is safe and well tolerated in Japanese breast cancer 
patients. When the patients were divided into 2 groups by median value (168 ng/mL) of plasma 
trough letrozole concentration, the overall incidence of the AEs was similar between high and 
low trough concentration groups. Incidence of hot flush, the most major AE, was comparable 
between the 2 groups. Increase of cholesterol occurred more frequently in the subjects with high 
letrozole concentration while arthralgia occurred more frequently in the subject with lower 
letrozole concentration. 
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Table 2-2: Comparison of incidence of study drug related adverse events (incidence 
>4%) between patients with high and low plasma letrozole concentration 
Study drug related AEs 
[n, (%)] 
Overall 
(N=88) 
Grouping by letrozole concentration 
 168 ng/mL 
(N=44) 
< 168 ng/mL 
(N=44) 
Total number of patients who 
experienced study drug related AEs
58 (65.9%) 30 (68.2%) 28 (63.6%) 
Hot flush 17 (19.3%) 9 (20.5%) 8 (18.2%) 
Blood cholesterol increased 15 (17.0%) 11 (25.0%) 4 (9.1%) 
Arthralgia 13 (14.8%) 5 (11.4%) 8 (18.2%) 
Blood alkaline phosphatase 
increased 
10 (11.4%) 5 (11.4%) 5 (11.4%) 
Alanine aminotransferase increased 8 (9.1%) 3 (6.8%) 5 (11.4%) 
Aspartate aminotransferase 
increased 
7 (8.0%) 3 (6.8%) 4 (9.1%) 
Headache 6 (6.8%) 1 (2.3%) 5 (11.4%) 
-glutamyltransferase increased 5 (5.7%) 2 (4.5%) 3 (6.8%) 
Nausea 5 (5.7%) 3 (6.8%) 2 (4.5%) 
Hypertension 4 (4.5%) 2 (4.5%) 2 (4.5%) 
Vomiting 4 (4.5%) 1 (2.3%) 3 (6.8%) 
Pruritus 4 (4.5%) 3 (6.8%) 1 (2.3%) 
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2) Logistic regression analysis between exposure and efficacy/safety of letrozole 
In order to quantitatively investigate the relationship between letrozole exposure and 
efficacy/safety in breast cancer patients, logistic regression analysis was performed. As the 
indicator of letrozole exposure, Cmin, Cmax and AUC0-24hr at steady state of each patient estimated 
by the PPK model post-hoc estimation were used. 
Exposure and efficacy: As the indicator of the efficacy, achievement of the clinical response 
(complete response or partial response) was used (Fig. 2-3). The logistic regression analysis 
indicated that probability to achieve the clinical response tends to be high in patients with high 
Cmin at steady state, but it was not statistically significant (Fig 2-3 (a), p=0.130). The estimated 
odds ratio to achieve the clinical response corresponds to 50 ng/mL Cmin increase was 1.296 
(95% CI: 0.927, 1.812). Similarly, the probability to achieve the clinical response tends to be 
high in patients with high Cmax (Fig 2-3 (b)) or AUC0-24hr (Fig 2-3 (c)) at steady state but not 
statistically significant (p=0.235 and p=0.129, respectively). As shown in Fig 2-4, there was 
similar trend for the clinical benefit (complete response, partial response or long no change). 
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Fig. 2-3: Relationship between exposure and achievement of the clinical response 
(complete response or partial response) 
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Complete response (CR): disappearance of all lesions continuing at least for 4 weeks 
Partial response (PR): more than 50% decrease as sum of measurable lesions continuing at least 
for 4 weeks 
Cross represents observed data and the line shows the logistic regression line. 
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Fig. 2-4: Relationship between exposure and achievement of the clinical benefit 
(complete response, partial response or long no change) 
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Complete response (CR): disappearance of all lesions continuing at least for 4 weeks 
Partial response (PR): more than 50% decrease as sum of measurable lesions continuing at least 
for 4 weeks 
Long no change (LNC): less than 50% decrease or less than 25% increase as sum of measurable 
lesion continuing for more than 24 weeks 
Cross represents observed data and the line shows the logistic regression line. 
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Exposure and safety: When the relationship between letrozole exposure and incidence of major 
adverse events (hot flush, increase of blood cholesterol, arthralgia and increase of liver 
enzymes) was investigated, significant correlation was observed between Cmin and incidence of 
cholesterol increase (Fig 2-5 (b), p<0.05) or -GTP increase(Fig 2-5 (d), p<0.05). The estimated 
odds ratios for occurrence of cholesterol increase and -GTP increase associated with 50 ng/mL 
Cmin increase were 1.600 (95% CI: 1.057, 2.421) and 1.844 (95% CI: 1.138, 2.986), 
respectively. Also, there was a trend for higher incidence of abnormality in the other liver 
function parameters with higher Cmin, but the relationship was not statistically significant. In 
contrast, there was no correlation between Cmin and the incidence of hot flush (Fig 2-5 (a)) or 
arthralgia (Fig 2-5 (c)). The relationships between Cmax or AUC0-24hr and the adverse events 
were similar to those for Cmin (data not shown). 
Demographics, baseline values of estrogens or baseline values of each laboratory test item 
did not significantly correlated with the incidence of the adverse events except for arthralgia. 
The incidence of the arthralgia significantly correlated with age (p<0.05), and the incidence is 
higher in elders (Fig 2-6). 
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Fig. 2-5: Relationship between letrozole exposure and incidence of adverse events 
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Fig. 2-5 (continued): Relationship between letrozole exposure and incidence of 
adverse events 
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Cross represents observed data and the line shows the logistic regression line. 
 
- 43 - 
Fig. 2-6: Relationship between age and incidence of arthralgia 
0
1
40 50 60 70 80
Pr
ob
ab
ilit
y 
of
 a
rth
ra
lg
ia
oc
cu
rr
en
ce
Age (year)
p<0.05
 
Cross represents observed data and the line shows the logistic regression line. 
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3. Discussion 
In the clinical trials in the breast cancer patients, the trough concentrations of letrozole were 
highly variable between patients, as the individual mean trough concentrations were in the range 
from 50 to 500 ng/mL. In order to assess the clinical implication of the inter-individual 
variability, relationship between the exposure and the efficacy or the safety was investigated. 
The plasma concentrations of estrone and estrone-sulfate were below detection limit in 
almost all patients and the estradiol level was decreased to 50% of the baseline regardless of 
letrozole concentration. These results indicate that the inhibitory effect of letrozole on the 
aromatase activity would have achieved plateau by daily administration of 2.5 mg letrozole and 
inter-individual variability of plasma letrozole concentration observed in the study would not 
affect its pharmacodynamics. Actually, the earlier phase I study indicated that suppression of 
the estrogens by letrozole achieves plateau by 2.5 mg daily dosage [48]. The clinical results are 
well aligned with the estimation based on the in vitro data. The inhibitory constant (Ki) of 
letrozole for aromatase in human placenta microsomes is 2.1 nM [10]. The plasma free 
(unbound to plasma protein) concentration of letrozole is estimated to be 20 to 200 ng/mL (70 
to 700 nM) in the breast cancer patients in the current study, using the plasma protein binding 
ratio of approximately 60% [エラー! 参照元が見つかりません。]. The plasma free letrozole 
concentration is 33 to 330-folds higher than the Ki value. The percent of the aromatase 
inhibition can be estimated to be 97.1% to 99.7% by using the following equation assuming that 
substrate concentration is much lower than Km value: Inhibition ratio = [Ifree] / (Ki + [Ifree]), 
where [Ifree] is plasma free letrozole concentration. Therefore, almost complete inhibition of 
aromatase is expected in the plasma letrozole concentration range observed in the clinical study. 
When relationship between exposure of letrozole and efficacy was explored, the probability 
to achieve the clinical response (complete response or partial response) tended to be high in 
patients with higher letrozole exposure, but the relationship was not obvious or statistically 
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significant. This is probably due to that letrozole almost completely inhibited aromatase activity 
at this concentration range and its clinical efficacy achieved plateau as observed for the estrogen 
levels. 
Similar to the efficacy, there was no correlation between the exposure to letrozole and 
incidence of hot flush, one of major adverse events for aromatase inhibitors [49]. Treatment of 
breast cancer patients with aromatase inhibitors decrease estrogen level and may lead to 
consequence of estrogen deprivation including menopausal symptoms, i.e., hot flush. Estrogens 
in plasma were below detection limit in almost all patients regardless of letrozole concentration 
in the study. This will be the reason for no direct relation between hot flush and letrozole level. 
The incidence of arthralgia was not correlated with the exposure to letrozole but age, suggesting 
that the arthralgia was caused by aging rather than letrozole. In contrast to hot flush and 
arthralgia, there was a significant correlation between Cmin of letrozole and incidence of 
cholesterol increase and -GTP elevation. Incidence of AST and ALT increase also tended to be 
high with higher plasma letrozole concentration, although not statistically significant. These 
results suggest that high plasma concentration of letrozole may lead cholesterol increase and 
liver enzyme elevation. However, those adverse events observed in the phase II studies were 
mild in Common Toxicity Criteria grade of 1 or 2 and did not result in discontinuation or 
interruption of letrozole treatment. Therefore, dose adjustment will not be necessary based on 
plasma concentration of letrozole or CYP2A6 genotype but the same dosage (2.5 mg) can be 
used. 
 
4. Summary 
 Systemic exposure of letrozole did not significantly influence its pharmacodynamics or 
anti-tumor efficacy in breast cancer patients. 
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 Incidence of cholesterol increase and -GTP elevation was higher in patients with high 
plasma letrozole concentration. Considering its wide therapeutic window, however, dose 
adjustment will not be necessary based on plasma concentration of letrozole. 
 
 
- 47 - 
Section 3: Influence of bilirubin on gene expression of metabolic enzymes 
in human hepatocyte 
 
1. Prolusion 
The PPK analysis using data from the Japanese postmenopausal women revealed that 
subjects with higher total bilirubin have higher CL/F of letrozole. The increase of total bilirubin 
from 0.5 mg/dL to 1.0 mg/dL corresponds to increase of CL/F from 1.09 L/hr to 1.26 L/hr. In 
general, bilirubin level is regarded as an indicator of hepatic function and elevated bilirubin 
level suggests hepatic impairment like hepatocyte damage and biliary obstruction [50, 51]. 
Because letrozole is mainly eliminated via hepatic metabolism, the PPK result was unexpected. 
One of the potential causes for the higher CL/F in patients with the elevated bilirubin is 
induction of metabolic enzymes by bilirubin. In order to investigate the cause of the positive 
correlation between bilirubin level and CL/F of letrozole, influence of bilirubin on mRNA 
expression of metabolic enzymes of letrozole (CYP2A6 and CYP3A4) was examined in human 
hepatocytes by the reverse transcription polymerase chain reaction (RT-PCR). To explore the 
mechanism of the influence, effect of bilirubin on CYPs, UGTs and nuclear receptors in human 
hepatocytes were also investigated. 
 
2. Results 
1) Influence of bilirubin on metabolic enzymes of letrozole 
Because letrozole is mainly metabolized by CYP2A6 at clinically relevant concentrations, 
influence of bilirubin on CYP2A6 mRNA was examined as a preliminary study. After treatment 
of cryopreserved human hepatocytes with 20 μg/mL bilirubin for 48 hours, mRNA of CYP2A6 
increased compared to vehicle control while mRNA of the constitutively expressed 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene did not change by bilirubin 
treatment (Fig. 3-1). To further explore the influence of bilirubin on metabolism of letrozole, 
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mRNA of CYP2A6 and CYP3A4, both of which are the metabolic enzymes of letrozole, were 
measured in the human hepatocytes after treatment by 1 μg/mL bilirubin, corresponding to 
physiologically normal level, or 40 μg/mL bilirubin, corresponding to hyperbilirubinemia, for 
48 hours. As a positive control, hepatocytes were also treated by 50μM rifampicin. As shown in 
Fig. 3-2 (a), CYP2A6 mRNA was not induced by 1 μg/mL bilirubin but induced to 1.7-folds by 
40 μg/mL bilirubin. In case of CYP3A4, neither 1 nor 40 μg/mL bilirubin induced mRNA (Fig. 
3-2 (b)). As mRNA of CYP3A4 was induced by the typical CYP3A4 inducer rifampicin, it is 
proved that the induction study could detect the induction potency appropriately. 
These results indicate that the higher CL/F in patients with elevated bilirubin shown by the 
PPK analysis is attributable to induction of CYP2A6 by bilirubin. 
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Fig. 3-1: RT-PCR analysis of GAPHD and CYP2A6 after treatment with bilirubin in 
primary culture of human hepatocytes 
(a) GAPDH (b) CYP2A6
 
Total RNA was isolated from human hepatocytes after 48 hours treatment with or without 
bilirubin and RT-PCR using specific primers for GAPDH and CYP2A6 was carried out 
followed by poly-acrylamide gel electrophoresis as described in Materials and methods 
 
Fig. 3-2: Influence of bilirubin on metabolic enzymes for letrozole 
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Each data represents mean + SD (N=3). 
CYP mRNA levels were determined by RT-PCR, and were normalized with those of GAPDH. 
*: Significantly different from vehicle control by Dunnett test (P<0.05) 
**: Significantly different from vehicle control by Dunnett test (P<0.01) 
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2) Influence of bilirubin on cytochrome P450 enzymes 
In order to further explore the influence of bilirubin on other hepatic metabolic enzymes, 
mRNA of CYPs expressed in human liver was measured (Fig. 3-3). As shown in Fig. 3-3 (a), 
CYP1A2 mRNA was increased to 1.4-folds of the vehicle control by 40 μg/mL bilirubin 
although the difference did not reach statistically significant level (p=0.0528). Compared to 
1 μg/mL bilirubin, it was increased to 1.8-folds by treatment of 40 μg/mL bilirubin. mRNA 
levels of other CYP enzymes did not change by the treatment of bilirubin. Rifampicin induced 
mRNA of CYP2B6 and CYP2C8. 
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Fig. 3-3: Influence of bilirubin on cytochrome P450 enzymes 
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Each data represents mean + SD (N=3). 
CYP mRNA levels were determined by RT-PCR, and were normalized with those of GAPDH. 
*: Significantly different from vehicle control by Dunnett test (P<0.05) 
**: Significantly different from vehicle control by Dunnett test (P<0.01)) 
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Fig. 3-3 (continued): Influence of bilirubin on cytochrome P450 enzymes 
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Each data represents mean + SD (N=3). 
CYP mRNA levels were determined by RT-PCR, and were normalized with those of GAPDH. 
*: Significantly different from vehicle control by Dunnett test (P<0.05) 
**: Significantly different from vehicle control by Dunnett test (P<0.01) 
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3) Influence of bilirubin on UGT 
Because bilirubin is conjugated with glucuronic acid by several UGT enzymes in humans, 
influence of bilirubin on mRNA levels of UGT was examined as self-regulation of its 
metabolism (Fig. 3-4). In our study, none of the UGT enzymes investigated was induced by the 
bilirubin treatment. In case of UGT1A6 which is one of the bilirubin conjugating enzymes, 
however, mRNA level decreased to 70% of the vehicle control by 1 μg/mL bilirubin and 
recovered to the vehicle control level by 40 μg/mL bilirubin (Fig. 3-4 (c)). This result suggests 
that under the physiologically relevant conditions, UGT1A6 may be induced by the elevated 
bilirubin concentration. 
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Fig. 3-4: Influence of bilirubin on UGT 
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Each data represents mean + SD (N=3). 
UGT mRNA levels were determined by RT-PCR, and were normalized with those of GAPDH. 
*: Significantly different from vehicle control by Dunnett test (P<0.05) 
**: Significantly different from vehicle control by Dunnett test (P<0.01) 
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Fig. 3-4 (continued): Influence of bilirubin on UGT 
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Each data represents mean + SD (N=3). 
UGT mRNA levels were determined by RT-PCR, and were normalized with those of GAPDH. 
*: Significantly different from vehicle control by Dunnett test (P<0.05) 
**: Significantly different from vehicle control by Dunnett test (P<0.01) 
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4) Influence of bilirubin on nuclear receptors 
In order to explore induction mechanisms of metabolic enzymes by bilirubin, influence of 
bilirubin on constitutive androstane receptor (CAR), pregnane X receptor (PXR), retinoid X 
receptor α (RXRα) and hepatocyte nuclear factor-4α (HNF-4α), which are reported to contribute 
for the CYP2A6 induction [52-59], was investigated (Fig. 3-5). CAR mRNA did not change by 
the bilirubin treatment. PXR, RXRα and HNF-4α tended to decrease by 1 μg/mL bilirubin and 
increase by 40 μg/mL bilirubin. These results suggest that under physiologically relevant 
conditions, PXR, RXRα and HNF-4α may be induced by the elevated bilirubin concentration. 
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Fig. 3-5: Influence of bilirubin on nuclear receptors 
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Each data represents mean + SD (N=3). 
Nuclear receptor mRNA levels were determined by RT-PCR, and were normalized with those 
of GAPDH. 
*: Significantly different from vehicle control by Dunnett test (P<0.05) 
**: Significantly different from vehicle control by Dunnett test (P<0.01) 
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3. Discussion 
The PPK analysis in postmenopausal Japanese women demonstrated that subjects with 
higher total bilirubin have higher CL/F of letrozole. In order to investigate the cause of the 
unexpected correlation between bilirubin and CL/F of letrozole, the influence of bilirubin on 
CYP2A6 and CYP3A4, both of which are the metabolic enzymes of letrozole, were examined. 
Current study showed that mRNA expression of CYP2A6 in human hepatocytes was induced by 
bilirubin in a concentration dependent manner. The treatment of the hepatocytes by 1 μg/mL 
bilirubin did not change the mRNA of CYP2A6 but treatment by 40 μg/mL bilirubin resulted in 
1.7-folds increase compared to the vehicle control. In case of CYP3A4, neither 1 nor 40 μg/mL 
bilirubin induced mRNA. These results prove that the higher CL/F of letrozole in patients with 
elevated bilirubin is attributable to induction of CYP2A6 by bilirubin. Although the magnitude 
of the CYP2A6 mRNA induction by bilirubin is not so large, marginal increase of CYP2A6 
activity will significantly affects CL/F of letrozole as the estimated value of CL/F by PPK 
analysis was 1.09 L/hour, which is much smaller than hepatic blood flow in humans (60 to 90 
L/hr [47, 61]) and means CL/F is hepatic intrinsic clearance rate limited. 
Rifampicin is well known for an agonist of PXR and induces CYP3A4 by activating PXR 
[62-64]. CYP2A6 is also reported to be induced by rifampicin via PXR [62-64]. Actually, 
CYP3A4 and CYP2A6 were induced by rifampicin treatment in the current study. Induction of 
CYP2B6, CYP2C8, UGT1A1 and UGT1A3, which are reported to be regulated by PXR [63-
68], by rifampicin was also observed. The induction profile of the enzymes by bilirubin 
observed in the study was different from the profile of rifampicin, suggesting that induction of 
CYP2A6 by bilirubin will not be caused via activation of PXR. 
It is reported that bilirubin causes translocation of CAR from hepatocyte cytoplasm to 
nucleus and induces UGT1A1 which is responsible for the glucuronidation of bilirubin [46]. 
Wortham et al suggested that CAR will regulate gene expression of CYP2A6 by regression 
analysis among several metabolic enzymes and transporters [69]. Also, Ito et al reported that 
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dimer of CAR and retinoid X receptor- binds to CYP2A6 gene [57]. Thus, it can be 
speculated that elevation of bilirubin level in plasma induces CYP2A6 activity via CAR 
translocation and increase letrozole clearance accordingly. CYP2B6, which is known to be 
induced by phenobarbital through CAR activation [52, 58], was somewhat induced by 
treatment of high bilirubin concentration (Fig. 3-3 (b)). However, mRNA of other enzymes 
known to be regulated by CAR such as CYP2C8, CYP2C9, CYP2C19, CYP3A4 and 
UGT1A1, was not induced by bilirubin. Pascussi et al. [59] suggested that CYP2A6 is more 
responsive to CAR: because CYP2A6 hydroxylates a variety of steroid hormones, including 
androgen and estrogens [70], and because CAR is activated by estrogens but inactivated by 
androgens [71]. Therefore, treatment with bilirubin higher than 40 μg/mL, which was used in 
the current study, may be required to induce those enzymes other than CYP2A6. Actually, it is 
reported that UGT1A1 was not induced by bilirubin at 30 μg/mL or lower but induced at 50 
μg/mL or higher [45], suggesting threshold around 30 to 50 μg/mL. 
Bilirubin is also known to be a ligand of human aryl hydrocarbon receptor (AhR) [72-75]. 
Actually, mRNA of CYP1A2, which is known to be regulated by AhR [76, 77], was tended to 
be increased by bilirubin treatment although not statistically significant (Fig. 3-3 (a)). It is 
reported that UGT1A6 also inducible by AhR activation [78]. The current study result suggests 
that UGT1A6 may be induced by the elevated bilirubin concentration (Fig. 3-4 (c)). However, 
contribution of AhR to the gene regulation of CYP2A6 is not known and thus contribution of 
the AhR activation by bilirubin to the induction of CYP2A6 is not clear. 
As shown in Fig. 3-5, it was suggested that PXR, RXR and HNF-4α may be induced by the 
elevated bilirubin concentration under physiologically relevant conditions. However, induction 
of CYP2A6 by bilirubin will not be through the induction of these nuclear receptors’ 
expression because the change of the mRNA levels of NRs by bilirubin did not correspond to 
CYP2A6 mRNA change. 
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In order to elucidate the induction mechanism of CYP2A6 by bilirubin, further studies e.g., 
knock down of the nuclear receptors by using siRNA [79] and overexpression of the nuclear 
receptors by using vectors [57], will be required. Because CYP2A6 is well known for the 
genetic polymorphism [33-36], difference of the bilirubin influence between the genotype 
should also be investigated. 
 
4. Summary 
 Bilirubin induces mRNA of CYP2A6 in human hepatocytes. 
 The induction mechanism of bilirubin cannot be fully clarified but will not be through PXR 
activation, or the induction of CAR, PXR, RXR and HNF-4α expression. 
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Section 4: Overall discussion and conclusion 
During drug development processes, elucidation of the PK profile of a drug candidate in the 
early development stage is quite important. If the compound is targeted to act transiently, e.g., 
suppression of the postprandial blood glucose level, sleep inducing and treatment of the 
migraine headache, swift absorption with relatively short elimination half-life is preferable. In 
case that the medicine is required to act for a certain period, e.g., prevention of the asthma 
attack during sleep, reduction of blood pressure and inhibition of the cell signal transduction for 
proliferation of the cancer cells, long retention in systemic circulation, i.e., relatively long 
elimination half-life is desirable. Not only overall PK profile but also assessment of the extent 
of the inter-individual variability in the PK profile is important since low exposure may cause 
insufficient efficacy and high exposure may result in unexpected adverse events [37-40]. If 
factors which cause the inter-individual variability can be identified and its clinical implications 
can be illustrated, the dosage and the administration of the drug can be tailored for each patient 
to achieve required efficacy without safety concern. 
The clinical studies implemented in healthy Japanese postmenopausal women revealed that 
letrozole is rapidly absorbed after oral administration and has the long elimination half-life of 
approximately 70 hours on average (Table 1-2). Because letrozole is the aromatase inhibitor 
and required to act continuously to suppress breast cancer proliferation, the PK profiles are 
suitable characteristics. However, the clinical studies also demonstrated quite substantial inter-
individual variability in letrozole PK (Fig. 1-2 and Fig. 1-3). To identify factors which affect 
disposition of letrozole, PPK analysis with non-linear mixed effects modeling was conducted. 
The analysis identified some factors (genotype of CYP2A6, body weight, serum creatinine and 
total bilirubin) which influence PK profile of letrozole. Of those covariates, the genotype of 
CYP2A6 most strongly influences CL/F of letrozole, the population mean of CL/F in subjects 
who possess only 1 reference allele and no reference allele were 77.5% and 41.2% of the value 
- 62 - 
in the subjects who have 2 reference alleles, respectively. This finding indicates that the 
letrozole systemic clearance is largely attributable to metabolism by CYP2A6. When the trough 
concentration of letrozole in breast cancer patients was compared between Japanese and 
Westerner, the trough level was significantly higher in Japanese. After grouping by CYP2A 
genotype, however, there was no significant difference between Westerner and Japanese with 2 
reference alleles (Fig. 1-5). Current intensive research to identify factors which influence PK 
profile of letrozole revealed that the difference observed between Japanese and Westerner is not 
due to ethnicity or race but difference of allele frequency of CYP2A6 mutation. Therefore, 
clinical evidences established in the Western population [8, 16-19] can be extrapolated to 
Japanese as no ethnic difference in PK is shown. 
It is reported that letrozole inhibits CYP2A6 activity with Ki value of 120 nM [20]. The 
plasma free (unbound to plasma protein) concentration of letrozole is estimated to be 20 to 200 
ng/mL (70 to 700 nM) in the breast cancer patients in the current study, using the plasma 
protein binding ratio of approximately 60% [10]. Thus, CYP2A6 activity may be inhibited in 
patients with high plasma letrozole concentration and caution is required when a drug which is 
metabolized by CYP2A6 and has narrow therapeutic window is co-administered with letrozole. 
The PPK model established in this study can be used to predict the individual plasma 
concentration of letrozole and to avoid unexpected drug-drug interactions. 
Although the inter-individual variability was elucidated and can be predicted by the PPK 
model, effect of the PK exposure difference on the clinical efficacy and safety must be 
evaluated for the proper application of the drug. When relationship between the exposure of 
letrozole and the efficacy was explored, there was no obvious or statistically significant 
relationship (Fig. 2-3 and Fig. 2-4). This is probably due to that letrozole almost completely 
inhibited aromatase activity at this concentration range and its clinical efficacy achieved plateau 
as observed for the estrogen levels. Regarding safety, there was a significant correlation 
between Cmin of letrozole and incidence of cholesterol increase and -GTP elevation. However, 
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those adverse events observed in the phase II studies were mild in Common Toxicity Criteria 
grade of 1 or 2 and did not result in discontinuation or interruption of letrozole treatment. 
Therefore, it is considered that the dose adjustment based on plasma letrozole concentration or 
CYP2A6 genotyping will not be required, with careful monitoring of liver function. 
 During the covariate analysis by the PPK approach, it was found that total bilirubin 
positively correlates with CL/F of letrozole. Because bilirubin level is regarded as an indicator 
of hepatic malfunction and letrozole is mainly eliminated via hepatic metabolism, the PPK 
result was unexpected. The experiment using the cryopreserved human hepatocytes revealed 
that bilirubin induces mRNA of CYP2A6 in a concentration dependent manner (Fig. 3-2). This 
result proves that the higher CL/F of letrozole in patients with elevated bilirubin is attributable 
to induction of CYP2A6 by bilirubin. Although the induction mechanism of bilirubin cannot be 
fully clarified, it will not be through PXR activation, or the induction of CAR, PXR, RXR and 
HNF-4α expression. Current study revealed some of the mechanisms of bilirubin influence on 
CL/F of letrozole. The attempt at elucidating the mechanism of the clinical finding by 
experiments, i.e., “bedside to bench” approach, can be a breakthrough in the scientific research 
field. 
Previously, the assessment of the inter-race/ethnicity difference of the exposure and the dose 
selection for the clinical application of a drug candidate were performed using the average 
exposure level and the overall efficacy and safety profiles. In this study, combination of 
methods with genotyping of metabolic enzyme, population pharmacokinetic analysis and 
logistic correlation analysis between the exposure and efficacy or safety was used to elucidate 
individual PK profile of letrozole and to illustrate the clinical implication of the variability in 
PK profile. Also, the in vitro study was performed to reveal the mechanism of the clinical 
observation. The methodology used in this study will be a future perspective of the drug 
development strategy to accelerate drug development with reducing the attrition rate, and 
facilitate to deliver the right drug to the right patients [80-83]. 
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In conclusion, this study revealed the factors which cause the large inter-individual 
variability in PK profile of letrozole and mechanism of the influence. These study results will 
facilitate the appropriate clinical application of letrozole. 
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Materials and methods 
 
Clinical studies 
Data from two phase I clinical trials in Japanese healthy postmenopausal women 
(CFEM345F1101 and CFEM345F1102) and two phase II clinical trials in Japanese 
postmenopausal women with advanced breast cancer (CFEM345F1201 and 
CFEM5F1203) were used in this analysis (Table 1-1). These studies were conducted in 
accordance with the World Medical Association's Declaration of Helsinki (1964, 
amended in 1975, 1983, 1989, 1996 and 2000), and Good Clinical Practice. The study 
protocol and the subject informed consent forms had been approved by ethical review 
board. Written informed consent for each subject was obtained prior to initiating any 
study procedures. 
Phase I study for single and 14-day multiple dosing (CFEM345F1101) 
This study consisted with single dose part and multiple dose part. Twelve healthy 
postmenopausal women received single oral dose of 2.5 mg letrozole for the single dose 
part and the same subjects were administered once daily dose of 2.5 mg letrozole for 14 
days for the multiple dose part. All of the 12 subjects provided peripheral blood for 
genotyping of CYP2A6. 
Phase I study for 28-day multiple dosing (CFEM345F1102) 
Ten healthy postmenopausal women received once daily dose of 2.5 mg letrozole 
orally for 28 days. All of the 10 subjects provided peripheral blood for genotyping of 
CYP2A6. 
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Phase II studies (CFEM345F1201 and CFEM5F1203) 
These studies were open-label, multi-center, non-randomized phase II trials to 
examine safety and efficacy of letrozole as monotherapy in postmenopausal women 
with advanced breast cancer. Postmenopausal women with histologically confirmed 
breast cancer were eligible for these studies. Patients were required to have tumors with 
estrogen receptor and/or progesterone receptor positive status or with both receptors 
unknown. Each patient received daily oral doses of 2.5mg letrozole until disease 
progression or any other event requiring discontinuation. In CFEM345F1201, 31 
patients were enrolled and 20 patients consented to genotyping of CYP2A6. In 
CFEM345F1203, 39 out of 57 enrolled patients agreed to provide blood sample for 
CYP2A6 genotyping. Data from these 59 patients who consented to genotyping were 
included to the PPK analysis dataset. 
 
Determination of letrozole in plasma 
The plasma letrozole concentrations obtained in studies CFEM345F1101, 
CFEM345F1102 and CFEM345F1201 were measured by validated HPLC method with 
fluorescence detection which was previously reported [84]. Following to solid phase 
extraction of letrozole from plasma by disposable C8 column, the sample was applied to 
the HPLC system. The chromatographic separation was achieved on Alltima C18 (150 
mm x 4.6 mm i.d., 5 m) column (Alltech, Templemare, France) at ambient 
temperature. The mobile phase consisted of a mixture of acetonitrile (40%) and 0.01 M 
phosphate buffer, pH 7 (60%), and was delivered isocratically at a flow-rate of 1.5 
ml/min. The excitation and emission wavelengths for the fluorescence detection were 
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230 and 295 nm, respectively. The limit of quantitation of letrozole in plasma was 1.00 
nM (0.29 ng/mL). 
The plasma letrozole trough levels obtained in CFEM345F1203 were measured by 
validated LC-MS/MS method following to sample processing by the solid phase 
extraction. The chromatographic separation was performed on Inertsil ODS-3 (100 mm 
x 4.6 mm i.d., 5 m) column (GL sciences, Tokyo, Japan) at a column temperature of 
40C using linear gradient elution with a mobile phase of 5 mM aqueous ammonium 
acetate and methanol (from 60:40 to 10:90 in 5 min) at a flow rate of 1.0 mL/min. A 
triple stage quadropole mass spectrometer equipped with an atmospheric pressure 
chemical ionization interface was used for detection. The spectrometer was operated in 
negative-ion mode with selected reaction monitoring mode. The mass transition selected 
to monitor letrozole was m/z 284 to a product ion at m/z 242. The lower limit of 
quantification with this method was 1.00 nM (0.29 ng/mL). 
 
Anti-tumor response 
In studies CFEM345F1201 and CFEM345F1203, efficacy of letrozole was evaluated 
according to the evaluation criteria for the treatment of advanced or recurrent breast 
cancer issued by the Japanese Breast Cancer Society. The criteria were; complete 
response (CR): disappearance of all lesion continuing at least for 4 weeks; partial 
response (PR): more than 50% decrease as sum of measurable lesion continuing at least 
for 4 weeks; no change (NC): less than 50% decrease or less than 25% increase as sum 
of measurable lesion continuing at least for 4 week; long NC: NC continuing for more 
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than 24 weeks; progressive disease (PD): more than 25% increase as sum of measurable 
lesion. 
 
Genotyping of CYP2A6 
Genotyping of CYP2A6 was carried out with genomic DNA isolated from peripheral 
blood. DNA extraction was performed with QIAamp DNA Blood Mini Kit (QIAGEN, 
Hilden, Germany), according to the manufacturer’s instruction. Genotype measured for 
CYP2A6 were CYP2A6*1A, *1B, *4, *7, *8, *9, *10, and *11 [33-36]. CYP2A6*1A is a 
wild type gene. CYP2A6*1B is gene conversion with CYP2A7 in 3’-untranslated region 
and expresses normal protein. CYP2A6*4 is whole gene deletion and does not express 
protein. CYP2A6*7 is a point mutation in exon 9 (T1412C). CYP2A6*8 is a point 
mutation in exon 9 (G1454T). CYP2A6*9 is a point mutation in TATA box (T-48G). 
CYP2A6*10 is a point mutations in exon 9 (combination of CYP2A6*7 and CYP2A6*8). 
CYP2A6*11 is a point mutation in exon 5 (T670C). Genotyping for CYP2A6*1A, *1B, 
*7, *8, *9, *10, and *11 were conducted by PCR-Invader method to detect the 
nucleotide change of the respective position, and genotyping for CYP2A6*4 was done 
by Invader copy number assay, according to Neville’s method [85]. The Invader 
reaction for the PCR-Invader assay (CYP2A6*1A, *1B, *7, *8, *9, *10, and *11) was 
performed at 63°C for 30 min, and the Invader reaction for Invader copy number assay 
(CYP2A6*4) was done at 63°C for 3 hours. Fluorescence was measured on Cytofluor 
4000 (Applied Biosystems, Foster City, CA, USA). 
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PPK analysis 
A non-linear mixed effects approach was used to estimate population parameters and 
inter-subject variability of these parameters. The model development and the parameter 
estimation were implemented in NONMEM version VI (GloboMax LLC, Hanover, 
MD, USA). The first order conditional estimation method was employed. A one-
compartment model with first-order absorption (ADVAN2 TRANS2 subroutine) was 
used as base model. The pharmacokinetic parameters estimated were CL/F, Vd/F and 
Ka. Inter-subject variability and residual error were assumed log-normally distributed 
and thus modeled using an exponential model. 
Subject specific characteristics such as body weight, age, laboratory test values and 
genotype of CYP2A6 were evaluated for their significance in the model to explain the 
inter-individual variability observed in PK parameters. In testing if a covariate X has 
any influence on the PK parameters, the following functional form of the covariate was 
used as a multiplier in the model structure: X for a dichotomous variable X taking 
value of 1 (for yes) and 0 (for no), and (X/Xmed) for a continuous variable X, where 
Xmed is the median value of X. At the first screening step, a significant covariate was 
selected if addition of the covariate resulted in a decrease in OFV more than 3.875. A 
difference of more than 3.875 between OFV of each model was regarded to be 
significant at the 0.05 level, approximated by the 2-distribution with one degree of 
freedom. Once significant covariates were screened, all of the significant covariates 
were included to the model to develop a full model. Final model was then developed by 
backward elimination step. During the stepwise backward model reduction, the 
covariate was retained in the model with an increase in OFV >6.814 (p <0.01). In 
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addition to OFV, the increase in precision of the variable estimate (% relative SE of 
prediction) and reduction in inter-individual variability were used in model selection. 
 
Exposure-response analysis 
To explore relationship between exposure to letrozole and clinical outcomes in breast 
cancer patients, logistic regression analysis was performed using SAS release 8.2 (SAS 
Institute Inc., Cary, NC, USA). Individual PK parameters were estimated by post hoc 
Bayesian estimation using the final PPK model, and used to derive letrozole exposure 
(Cmax, Cmin and AUC0-24hr) at steady-state. The calculated exposure was used as an 
independent variable. Achievement of CR, PR or LCN as an efficacy endpoint and 
incidence of adverse drug events were used for dependent variables of the logistic 
analysis. As the adverse drug events, hot flush, cholesterol increase, ALP increase, AST 
increase, ALT increase and -GTP increase, which were adverse events with an 
incidence of more than 5% in the phase II studies, were selected. The laboratory test 
abnormalities were treated as adverse events if investigator considered the change was 
clinically significant. 
 
Cell culture 
Cryopreserved human hepatocytes (60-year-old Caucasian male, Celsis IVT, 
Baltimore, MD, USA) were thawed at 37°C, suspended in thawing medium without 
glucose (Biopredic International, Rennes, France), and centrifuged at 160 x g for 2 min. 
Hepatocytes were resuspended in William’s medium E supplemented with 10% FBS, 4 
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μg/mL bovine insulin, 100 IU/mL penicillin and 100 μg/mL streptomycin and cultured 
in a collagen-coated 24-well plate (BD Biosciences, Franklin Lakes, NJ, USA) at a 
density of 0.25 x 106 cells/500 μL/well in a 37°C incubator with 5% CO2 and 95% air. 
After 4 hours, the culture medium was replaced with serum-free William’s medium E 
supplemented with 4 μg/mL bovine insulin, 100 IU/mL penicillin, 100 μg/mL 
streptomycin and 50 μM hydrocortisone hemisuccinate (incubation medium), and 
cultured for 20 hours in a CO2 incubator. Then, the medium was replaced with the 
incubation medium containing 1 μg/mL bilirubin (Wako Pure Chemical Industries, 
Osaka, Japan), 40 μg/mL bilirubin or 50 μM rifampicin and cultured for 24 hours in a 
CO2 incubator. After the replacement of the medium with the freshly prepared 
incubation medium containing bilirubin or rifampicin, the cells were further incubated 
for 24 hours before total RNA extraction for RT-PCR. 
 
RT-PCR 
At the end of the culture period, the medium was removed and total RNA was extracted from 
human hepatocytes using TRIzol reagent (Life Technologies Corporation, Carlsbad, CA, USA) 
according to manufacturers' protocols. The concentration and purity of RNA were determined 
spectrometrically. 
Reverse transcription was performed using the TaKaRa RNA PCR Kit (AMV) Ver.3.0 
(Takara Bio Co., Ltd, Shiga, Japan), according to the manufacturer’s instruction. Total RNA 
(400 ng) was mixed with reaction buffer, 5 mM MgCl2, dNTP mixture (1 mM each), RNase 
inhibitor (1 U/μL), AMV reverse transcriptase XL (0.25 U/μL), and random 9 mers (2.5 μM) in 
a final volume of 20 μL. The reaction mixture was incubated at 30°C for 10 min followed by 
42°C for 30 min and then heated at 95°C for 5 min to inactivate the enzyme. 
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PCR was carried out using the TaKaRa PrimeSTAR Max DNA Polymerase (Takara Bio Co., 
Ltd, Shiga, Japan), according to the manufacturer’s instruction. The reaction was performed in a 
total volume of 10 μL consisting of 2 x PrimeSTAR Max Premix, 0.3 μM forward primer, 0.3 
μM reverse primer and the reverse transcription product as a template corresponding to 2 ng 
RNA. The amplification was performed by denaturation at 98°C for 10 sec, annealing at an 
appropriate temperature for 5 sec, and extension at 72°C for 5 sec for appropriate cycles. The 
primers used, the annealing temperatures and number of cycles of the PCR were listed in 
Appendix-1. The number of cycles was optimized to fall within a linear amplification range. 
The amplified PCR products were separated by polyacrylamide gel electrophoresis on 8% 
polyacrylamide gel, followed by staining with SYBR Green I Nucleic Acid Gel Stain (Cambrex 
Bio Science Rockland, Inc., Rockland, ME, USA) and detection using ChemiDoc XRS plus 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). Quantification of the target gene band was 
performed by Quantity One (Bio-Rad Laboratories, Inc., Hercules, CA, USA). To standardize 
the amount of sample, the calculated amount of the gene of interest was divided by the 
calculated amount of the constitutively expressed glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) gene in the sample. These normalized amounts were then used to compare the 
relative amount of target mRNA between different samples. 
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Appendix-1: Sequence of primers used for RT-PCR analyses 
Gene Primer Sequence Product size 
(bp) 
Annealing 
temperature (°C) 
PCR cycle 
number 
CYP2A6 Forward 5’-TTTTGGTGGCCTTGCTGGT-3’ 152 60 29 
 Reverse 5’-GGAGTTGTACATCTGCTCTGTGTTCA-3’    
CYP3A4 Forward 5’-GATTGACTCTCAGAATTCAAAAGAAACTGA-3’ 149 60 29 
 Reverse 5’-GGTGAGTGGCCAGTTCATACATAATG-3’    
CYP1A2 Forward 5’-TGTTCAAGCACAGCAAGAAGG-3’ 92 60 32 
 Reverse 5’-TGCTCCAAAGACGTCATTGAC-3’    
CYP2B6 Forward 5’-CCCCAAGGACACAGAAGTATTTC-3’ 83 60 32 
 Reverse 5’-GATTGAAGGCGTCTGGTTTTTC-3’    
CYP2C8 Forward 5’-GGACTTTATGGATTGCTTCCTG-3’ 144 60 28 
 Reverse 5’-CCATATCTCAGAGTGGTGCTTG-3’    
CYP2C9 Forward 5’-GACATGAACAACCCTCAGGACTTT-3’ 145 60 28 
 Reverse 5’-TGCTTGTCGTCTCTGTCCCA-3’    
CYP2C19 Forward 5’-GAACACCAAGAATCGATGGACA-3’ 196 60 28 
 Reverse 5’-TCAGCAGGAGAAGGAGAGCATA-3’    
CYP2D6 Forward 5’-CCTACGCTTCCAAAAGGCTTT-3’ 193 60 30 
 Reverse 5’-AGAGAACAGGTCAGCCACCACT-3’    
CYP3A5 Forward 5’-CCTTACCCCAGTTTTTGAAGCA-3’ 198 60 30 
 Reverse 5’-TCCAGATCAGACAGAGCTTTGTG-3’    
UGT1A1 Forward 5’-CCTTGCCTCAGAATTCCTTC-3’ 234 60 28 
 Reverse 5’-ATTGATCCCAAAGAGAAAACCAC-3’    
UGT1A3 Forward 5’-GTTGAACAATATGTCTTTGGTCT-3’ 585 55 30 
 Reverse 5’-ATTGATCCCAAAGAGAAAACCAC-3’    
 
- 75 - 
Appendix-1 (continued): Sequence of primers used for RT-PCR analyses 
Gene Primer Sequence Product size 
(bp) 
Annealing 
temperature (°C) 
PCR cycle 
number 
UGT1A6 Forward 5’-CAACTGTAAGAAGAGGAAAGAC-3’ 102 60 30 
 Reverse 5’-ATTGATCCCAAAGAGAAAACCAC-3’    
UGT2B4 Forward 5’-TGGTGAGCTGCTGGCCGAGT-3’ 283 55 30 
 Reverse 5’-CATTGTCTCAAATAATGTAGTG-3’    
UGT2B7 Forward 5’-GGAAATCATGTCAATATTTGG-3’ 412 55 30 
 Reverse 5’-CATTGTCTCAAATAATGTAGTG-3’    
UGT2B10 Forward 5’-TGACATCGTTTTTGCAGATGCTTA-3’ 316 55 30 
 Reverse 5’-CATTGTCTCAAATAATGTAGTG-3’    
UGT2B15 Forward 5’-GTGTTGGGAATATTATGACTACAGTAAC-3’ 406 55 28 
 Reverse 5’-CATTGTCTCAAATAATGTAGTG-3’    
CAR Forward 5’-GCAAGGGTTTCTTCAGGAGAAC-3’ 72 55 32 
 Reverse 5’-CTTCACAGCTTCCAGCAAAGG-3’    
HNF-4 Forward 5’-GAGGAACCAGTGCCGCTACT-3’ 71 60 32 
 Reverse 5’-TCTGGACGGCTTCCTTCTTC-3’    
PXR Forward 5’-GGCCACTGGCTATCACTTCAA-3’ 70 60 32 
 Reverse 5’-TTTCATGGCCCTCCTGAAAA-3’    
RXR Forward 5’-AAGGACCGGAACGAGAATGA-3’ 68 60 30 
 Reverse 5’-ATCCTCTCCACCGGCATGT-3’    
GAPDH Forward 5’-CCAGGGCTGCTTTTAACTC-3’ 292 60 29 
 Reverse 5’-GCTCCCCCCTGCAAATGA-3’    
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